Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, Isis to Co-develop microRNA-based Drugs for Liver Cancer

NEW YORK, Feb. 22 (GenomeWeb News) - Isis Pharmaceuticals and Rosetta Genomics plan to co-discover and -develop antisense drugs that regulate microRNAs for the treatment of hepatocellular carcinoma, the companies said today.


The alliance will rely on Rosetta's database of miRNA genes and Isis' expertise in oligonucleotide chemistry and antisense drug discovery and development.


Financial terms of the deal were not disclosed.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.